Tumor News and Research

RSS

Software manipulates 3-D holograms of various organs obtained from ultrasound, CT or MRI scans

Recently converted in one of the youngest residents of Silicon Valley, California, the high-tech Mexican enterprise Echopixel created software that allows the medical doctor to look and manipulate on their desk third dimension (3-D) holograms of various organs obtained from ultrasound, CT or MRI scans.

7 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

Researchers start Phase I clinical trial of implantable vaccine for treatment of melanoma

A cross-disciplinary team of scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.

7 Sep 2013

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.

7 Sep 2013

BMP linked to increased risk of benign tumors, not cancers

Patients undergoing spinal fusion surgery with bone morphogenetic protein (BMP) appear to be at increased risk of benign tumors—but not cancers, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

7 Sep 2013

New Sponge-Based Therapeutic Cancer Vaccine Begins Human Clinicals

...

6 Sep 2013

Trovagene, University of Southern California enter into clinical collaboration agreement

Trovagene, Inc., a developer of molecular diagnostics for cancer monitoring, today announced that the Company has entered into a clinical collaboration agreement with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using Trovagene's proprietary cell-free DNA assays.

6 Sep 2013

TSRI scientists identify involvement of angiomotin protein in cancer

A team led by scientists from The Scripps Research Institute have shown that a protein once thought to inhibit the growth of tumors is instead required for initial tumor growth.

6 Sep 2013

Myeloid derived suppressor cells provide niche where cancer stem cells survive

The immune system is normally known for protecting the body from illness. But a subset of immune cells appear to be doing more harm than good.

6 Sep 2013

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival -- up to two years -- among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.

6 Sep 2013

Scientists develop robotic systems for image-guided removal of hard-to-reach brain tumors

NIBIB-funded scientists and engineers are teaming up with neurosurgeons to develop technologies that enable less invasive, image-guided removal of hard-to-reach brain tumors.

6 Sep 2013

Researchers develop method for purifying cardiac muscle cells using molecular beacons

Pure cardiac muscle cells, ready to transplant into a patient affected by heart disease. That's a goal for many cardiology researchers working with stem cells. Having a pure population of cardiac muscle cells is essential for avoiding tumor formation after transplantation, but has been technically challenging.

6 Sep 2013

TSRI scientists discover isoform of angiomotin protein responsible for tumorigenesis

A team led by scientists from The Scripps Research Institute (TSRI) have shown that a protein once thought to inhibit the growth of tumors is instead required for initial tumor growth. The findings could point to a new approach to cancer treatment.

5 Sep 2013

New laser-based tool could improve accuracy of brain tumor surgery

In the battle against brain cancer, doctors now have a new weapon -- a new imaging technology that will make brain surgery dramatically more accurate by allowing surgeons to distinguish -- at a microscopic level -- between brain tissue and tumors.

5 Sep 2013

New laser-based technology may make brain tumor surgery more accurate

A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor.

5 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Myriad, Astrazeneca Expand Collaboration On Olaparib

...

4 Sep 2013

New method to detect genetic variations that initiate colon cancer

A new, highly sensitive method to detect genetic variations that initiate colon cancer could be readily used for noninvasive colon cancer screening, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

4 Sep 2013

Microencapsulated brain cancer drug may simplify treatment and provide tightly controlled therapy

Consistently uniform, easily manufactured microcapsules containing a brain cancer drug may simplify treatment and provide more tightly controlled therapy, according to Penn State researchers.

4 Sep 2013

Researchers discover new way to target senescent cancer cells for destruction

Resting cancer cells can be selectively destroyed by inhibiting their energy metabolism. This is the recent discovery by researchers at Charité Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine (MDC) in Berlin-Buch, together with other cooperation partners from Germany. The findings of their study have been published in the scientific journal Nature.

4 Sep 2013

Tumor News and Research

Software manipulates 3-D holograms of various organs obtained from ultrasound, CT or MRI scans

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

Researchers start Phase I clinical trial of implantable vaccine for treatment of melanoma

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

BMP linked to increased risk of benign tumors, not cancers

New Sponge-Based Therapeutic Cancer Vaccine Begins Human Clinicals

Trovagene, University of Southern California enter into clinical collaboration agreement

TSRI scientists identify involvement of angiomotin protein in cancer

Myeloid derived suppressor cells provide niche where cancer stem cells survive

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Scientists develop robotic systems for image-guided removal of hard-to-reach brain tumors

Researchers develop method for purifying cardiac muscle cells using molecular beacons

TSRI scientists discover isoform of angiomotin protein responsible for tumorigenesis

New laser-based tool could improve accuracy of brain tumor surgery

New laser-based technology may make brain tumor surgery more accurate

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Myriad, Astrazeneca Expand Collaboration On Olaparib

New method to detect genetic variations that initiate colon cancer

Microencapsulated brain cancer drug may simplify treatment and provide tightly controlled therapy

Researchers discover new way to target senescent cancer cells for destruction

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News